| Literature DB >> 34294768 |
Qianhui Song1,2, Hao Yan1,2, Zanzhe Yu1,2, Zhenyuan Li1,2, Jiangzi Yuan1,2, Zhaohui Ni1,2, Wei Fang3,4.
Abstract
Assisted PD is used as an alternative option for the growing group of frail, older ESKD patients unable to perform their own PD. This study was undertaken to investigate the outcomes of assisted PD in older patients by comparing assisted PD patients with self-care PD patients. This study included all patients aged 70 and above who started on PD in our hospital from 2009 to 2018. Patients were followed up until death, PD cessation or to the end of the study (December 31, 2019). Risk factors associated with mortality, peritonitis and technique failure were evaluated using both cause-specific hazards and subdistribution hazards models. 180 patients were enrolled, including 106 (58.9%) males with a median age of 77.5 (77.2-81.2) years. Among the 180 patients, 62 patients (34.4%) were assisted. Patients on assisted PD group were older, more likely to be female, more prevalent in DM and CVD, with a higher Charlson score than patients undergoing self-care PD (P all < 0.05). In the multivariable analysis, assisted patients had a comparable patient survival and peritonitis-free survival compared to self-care PD patients either in the Cox or in the FG models. According to a Cox model, the use of assisted PD was associated with a lower risk of technique failure (cs-HR 0.20, 95% CI 0.04-0.76), but the association lost its statistical significance in the Fine and Gray model. Our results suggest that assisted PD could be a safe and effective KRT modality for older ESKD patients who need assistance.Entities:
Year: 2021 PMID: 34294768 PMCID: PMC8298431 DOI: 10.1038/s41598-021-94032-8
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Patient enrollment and follow-up. Abbreviations: PD peritoneal dialysis, HD hemodialysis.
Demographic and laboratory data of the study patients.
| Variable | All PD patients (n = 180) | Assisted PD group (n = 62) | Self-care PD group (n = 118) | |
|---|---|---|---|---|
| Age (years) | 77.5 (77.2–81.2) | 80.7 (76.9–84.0) | 75.6 (72.5–79.2) | < 0.001 |
| Gender (male) [n (%)] | 106 (58.9) | 30 (48.4) | 76 (64.4) | 0.038 |
| BMI (kg/m2) | 22.6 (20.4–24.7) | 21.9 (20.3–25.0) | 23.1 (20.4–24.6) | 0.606 |
| Charlson’s comorbidity index | 6.0 (6.0–7.0) | 7.0 (6.0–8.0) | 6.0 (5.0–7.0) | < 0.001 |
| Chronic glomerulonephritis | 46 (25.5) | 17 (27.4) | 29 (24.6) | 0.678 |
| Diabetic nephropathy | 38 (21.1) | 16 (25.8) | 22 (18.6) | 0.263 |
| Hypertension | 11 (6.1) | 3 (4.8) | 8 (6.8) | 0.850 |
| Polycystic kidney disease | 2 (1.1) | 0 (0) | 2 (1.7) | 0.546 |
| Others | 20 (11.1) | 6 (9.7) | 14 (11.9) | 0.657 |
| Unknown | 63 (35.0) | 20 (32.3) | 43 (36.4) | 0.576 |
| Diabetes mellitus | 69 (38.3) | 30 (48.4) | 39 (33.1) | 0.044 |
| Hypertension | 157 (87.2) | 56 (90.3) | 101 (85.6) | 0.366 |
| Cardiovascular disease | 64 (35.6) | 29 (46.8) | 35 (29.7) | 0.023 |
| Others | 41 (22.8) | 16 (25.8) | 25 (21.1) | 0.482 |
| Hemoglobin (g/L) | 86.7 ± 16.8 | 83.9 ± 15.5 | 88.2 ± 17.4 | 0.110 |
| Albumin (g/L) | 33.1 (29.1–36.4) | 33.1 (28.8–36.3) | 32.9 (29.9–36.6) | 0.998 |
| Creatinine (mmol/L) | 663.0 (527.9–789.0) | 628.5 (486.8–791.5) | 674.3 (555.2–796.8) | 0.231 |
| Blood urea nitrogen (mmol/L) | 26.5 (21.0–32.2) | 27.6 (21.2–33.6) | 26.4 (21.0–31.4) | 0.405 |
| Uric acid (mmol/L) | 487.5 ± 132.0 | 480.4 ± 130.4 | 491.2 ± 133.2 | 0.606 |
| Estimated glomerular filtration rate (eGFR) (mL/min/m2) | 5.7 (4.5–7.2) | 5.4 (4.4–7.9) | 5.7 (4.5–7.0) | 0.686 |
| Sodium (mmol/L) | 138.1 (136.0–142.0) | 138.4 (137.0–141.2) | 138.1 (136.0–142.0) | 0.175 |
| Potassium (mmol/L) | 4.1 ± 0.8 | 4.1 ± 0.8 | 4.2 ± 0.7 | 0.590 |
| Total cholesterol (mmol/L) | 4.5 (3.8–5.2) | 4.7 (3.7–5.2) | 4.5 (3.9–5.4) | 0.395 |
| Total triglycerides (mmol/L) | 1.3 (1.0–1.8) | 1.2 (0.9–1.7) | 1.4 (1.0–1.8) | 0.154 |
| Corrected calcium (mmol/L) | 2.1 (2.0–2.3) | 2.2 (2.0–2.3) | 2.1 (2.0–2.3) | 0.972 |
| Phosphate (mmol/L) | 1.8 (1.5–2.1) | 1.8 (1.4–2.1) | 1.8 (1.5–2.0) | 0.784 |
| Intact parathyroid hormone (iPTH) (pg/L) | 275.2 (160.5–423.0) | 264.0 (171.2–410.5) | 285.0 (137.0–424.7) | 0.938 |
| Hs-CRP (mg/L) | 4.5 (1.3–13.5) | 3.8 (1.5–13.8) | 5.0 (1.2–13.9) | 0.654 |
| Fasting blood glucose (mmol/L) | 5.0 (4.4–5.6) | 4.9 (4.5–6.1) | 4.4 (4.4–5.5) | 0.537 |
Values expressed as mean ± standard deviation, median (25th–75th percentile), or absolute numbers with percentages [n (%)].
Abbreviations: BMI body mass index, Hs-CRP high-sensitivity C reaction protein, Corrected calcium total calcium (corrected by albumin), Kt/Vurea urea kinetics, CrCl creatinine clearance, RRF residual renal function, nPCR normalized protein catabolic rate, D/Pcr peritoneal transport characteristics.
Baseline Laboratory results* was evaluated at PD initiation (within one week before PD catheterization).
Small solute clearance and peritoneal transport characteristics.
| Variable | All PD patients (n = 180) | Assisted PD group (n = 62) | Self-care PD group (n = 118) | |
|---|---|---|---|---|
| Total Kt/V urea | 2.08 (1.74–2.43) | 2.10 (1.78–2.50) | 2.07 (1.70–2.41) | 0.460 |
| Total CrCl (L/week/1.73m2) | 68.9 (55.9–87.2) | 68.8 (54.0–92.1) | 68.9 (55.9–86.7) | 0.744 |
| RRF (mL/min/1.73 m2) | 3.09 (1.67–5.04) | 3.03 (1.62–5.24) | 3.05 (1.64–5.09) | 0.931 |
| nPCR (g/kg/day) | 0.82 (0.71–0.96) | 0.82 (0.72–0.95) | 0.82 (0.70–0.97) | 0.930 |
| D/Pcr | 0.65 (0.56–0.75) | 0.66 (0.56–0.71) | 0.64 (0.57–0.75) | 0.994 |
Values expressed as mean ± standard deviation, median (25th–75th percentile), or absolute numbers with percentages [n (%)].
Abbreviations: Kt/Vurea urea kinetics, CrCl creatinine clearance, RRF residual renal function, nPCR normalized protein catabolic rate, D/Pcr peritoneal transport characteristics.
Outcomes of the patients.
| Variable | All PD patients | Assisted PD group | Self-care PD group | |
|---|---|---|---|---|
| Follow-up (months) | 32.5 (15.7–42.7) | 32.5 (20.7–43.7) | 33.0 (12.9–49.7) | < 0.001 |
| Death | 100 (55.6) | 39 (62.9) | 61 (51.7) | 0.150 |
| Transfer to HD | 16 (8.9) | 3 (4.8) | 13 (11.0) | 0.166 |
| Transfer to other centers | 6 (3.3) | 0 (0) | 6 (5.1) | 0.095 |
| Recovery of renal function | 2 (1.1) | 1 (1.6) | 1 (1.0) | 1.000 |
| Dialysis independent | 1 (0.6) | 0 (0) | 1 (1.0) | 1.000 |
| Lost to follow-up | 1 (0.6) | 0 (0) | 1 (1.0) | 1.000 |
| Still on PD | 54 (30.0) | 19 (30.6) | 35 (29.7) | 0.891 |
| Cardiovascular disease | 32 (32) | 13 (21.0) | 19 (31.1) | 0.819 |
| Cardiac | 19 (19.0) | 8 (12.9) | 11 (18.0) | 0.758 |
| Cerebrovascular | 3 (3.0) | 0 (0) | 3 (4.9) | 0.279 |
| Peripheral vascular | 1 (1.0) | 1 (2.6) | 0 (0) | 0.390 |
| Sudden death | 9 (9.0) | 4 (6.5) | 5 (8.2) | 1.000 |
| Infection | 26 (26.0) | 12 (30.8) | 14 (23.0) | 0.385 |
| Peritonitis | 3 (3.0) | 0 (0) | 3 (4.9) | 0.421 |
| Pneumonia | 18 (18.0) | 10 (25.6) | 8 (13.1) | 0.121 |
| Sepsis | 5 (5.0) | 2 (5.2) | 3 (4.9) | 0.948 |
| Cancer | 9 (9) | 3 (7.7) | 6 (9.8) | 0.994 |
| Gastrointestinal hemorrhage | 6 (6.0) | 1 (2.6) | 5 (8.2) | 0.400 |
| Others | 11 (11.0) | 3 (4.8) | 8 (13.1) | 0.849 |
| Unknown | 16 (16.0) | 7 (11.3) | 9 (14.8) | 0.671 |
| Peritonitis | 7 (43.8) | 2 (66.7) | 5 (38.5) | 0.550 |
| Catheter complications | 2 (12.5) | 0 (0) | 2 (15.4) | 0.546 |
| Inadequate dialysis | 0 (0) | 0 (0) | 0 (0) | |
| Others | 7 (43.8) | 1 (33.3) | 6 (46.2) | 0.425 |
| Total number of episodes | 101 | 28 | 73 | |
| Peritonitis rate (episode per patient-year) | 0.195 | 0.155 | 0.216 | |
| Peritonitis-free [n (%)] | 118 (65.6) | 39 (62.9) | 79 (66.9) | 0.587 |
| Failed treatment for peritonitis * [n (%)] | 16 (8.9) | 5 (8.1) | 11 (9.3) | 0.778 |
Failed treatment for peritonitis* was defined as discontinuation of PD including temporary or permanent transfer to hemodialysis or peritonitis-related deaths; Peritonitis-related deaths included death directly caused by active peritonitis or within 4 weeks of a peritonitis episode, or any death during hospitalization for peritonitis.
Figure 2Kaplan–Meier curves by assistance for patient survival (A), peritonitis-free survival (B) and technique survival (C).
Adjusted cs-HRs (Cox model) and sd-HR (Fine and Gray model) for each event.
| Variable | Death | Peritonitis | Transfer to HD | |||
|---|---|---|---|---|---|---|
| cs-HR (95% CI) | sd-HR (95% CI) | cs-HR (95% CI) | sd-HR (95% CI) | cs-HR (95% CI) | sd-HR (95% CI) | |
| Age | 1.09 (1.04–1.14)*** | 1.05 (1.01–1.09)* | 1.05 (0.99–1.11) | 1.01 (0.95–1.09) | 1.15 (1.02–1.31)* | 1.05 (0.89–1.24) |
| Male Gender | 1.22 (0.78–1.91) | 1.26 (0.80–1.98) | 1.16 (0.68–1.99) | 1.07 (0.61–1.86) | 0.30 (0.07–1.36) | 0.39 (0.11–1.34) |
| BMI | 0.99 (0.93–1.06) | 0.94 (0.89–1.00) | 1.07 (0.99–1.16) | 1.06 (0.96–1.17) | 1.31 (1.11–1.55)** | 1.25 (1.02–1.54)* |
| Diabetes | 0.85 (0.55–1.32) | 1.06 (0.68–1.64) | 0.95 (0.55–1.64) | 1.02 (0.59–1.76) | 0.35 (0.11–1.10) | 1.64 (0.67–4.05) |
| CVD | 1.87 (1.23–2.83)* | 1.59 (1.05–2.41)* | 0.85 (0.48–1.51) | 0.62 (0.35–1.11) | 1.17 (0.30–4.48) | 0.40 (0.09–1.78) |
| Hemoglobin | 0.99 (0.97–0.99)* | 0.99 (0.98–1.00) | 0.99 (0.97–1.00) | 0.99 (0.98–1.01) | 0.99 (0.96–1.03) | 1.00 (0.97–1.03) |
| Albumin | 1.00 (0.97–1.03) | 0.99 (0.96–1.02) | 1.00 (0.96–1.03) | 0.99 (0.96–1.02) | 1.05 (0.96–1.16) | 1.06 (0.97–1.15) |
Abbreviations: cs-HR cause-specific hazard ratio, sd-HR subdistribution hazard ratio, CI confidence interval, BMI body mass index, CVD cardiovascular disease, RRF residual renal function.
*P < 0.05, **P < 0.01, ***P < 0.001.
aRRF group was defined as: high RRF group, residual renal function (RRF) > median; low RRF group, residual renal function (RRF) < median.